State of the art and upcoming trends in HER2-directed therapies in gastrointestinal malignancies.

IF 2.8 4区医学 Q2 ONCOLOGY

Current Opinion in Oncology Pub Date : 2024-07-01 Epub Date: 2024-05-01 DOI:10.1097/CCO.0000000000001043

Jaeyop Lee, Geoffrey Ku

{"title":"State of the art and upcoming trends in HER2-directed therapies in gastrointestinal malignancies.","authors":"Jaeyop Lee, Geoffrey Ku","doi":"10.1097/CCO.0000000000001043","DOIUrl":null,"url":null,"abstract":"Purpose of review: This review critically evaluates the evolution and current status of human epidermal growth factor receptor 2 (HER2)-directed therapies in upper gastrointestinal (GI) malignancies, a timely and relevant inquiry given the dynamic shifts in therapeutic strategies over the past decade. Initial enthusiasm following the Trastuzumab for Gastric Cancer (ToGA) study's demonstration of trastuzumab's efficacy, however, encountered hurdles due to subsequent trials showing limited progress, underscoring the necessity for a reevaluation of therapeutic approaches and the exploration of novel agents.Recent findings: The review highlights significant breakthroughs in the form of immune checkpoint inhibitors and innovative therapeutic technologies, which have redefined treatment paradigms and shown promising efficacy in HER2-positive cases. Emerging treatments such as trastuzumab deruxtecan (T-DXd), zanidatamab and evorpacept further illustrate the ongoing efforts to leverage unique mechanisms of action for improved HER2-positive antitumor activity.Summary: The advancements in HER2-directed therapies underscore a pivotal era in the management of upper GI malignancies. These developments not only reflect the profound impact of integrating novel therapeutic combinations but also highlight the critical role of ongoing research in overcoming resistance mechanisms and tailoring treatment to individual disease profiles.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"326-331"},"PeriodicalIF":2.8000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11611523/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/CCO.0000000000001043","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/1 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: This review critically evaluates the evolution and current status of human epidermal growth factor receptor 2 (HER2)-directed therapies in upper gastrointestinal (GI) malignancies, a timely and relevant inquiry given the dynamic shifts in therapeutic strategies over the past decade. Initial enthusiasm following the Trastuzumab for Gastric Cancer (ToGA) study's demonstration of trastuzumab's efficacy, however, encountered hurdles due to subsequent trials showing limited progress, underscoring the necessity for a reevaluation of therapeutic approaches and the exploration of novel agents.

Recent findings: The review highlights significant breakthroughs in the form of immune checkpoint inhibitors and innovative therapeutic technologies, which have redefined treatment paradigms and shown promising efficacy in HER2-positive cases. Emerging treatments such as trastuzumab deruxtecan (T-DXd), zanidatamab and evorpacept further illustrate the ongoing efforts to leverage unique mechanisms of action for improved HER2-positive antitumor activity.

Summary: The advancements in HER2-directed therapies underscore a pivotal era in the management of upper GI malignancies. These developments not only reflect the profound impact of integrating novel therapeutic combinations but also highlight the critical role of ongoing research in overcoming resistance mechanisms and tailoring treatment to individual disease profiles.

查看原文本刊更多论文

胃肠道恶性肿瘤中 HER2 靶向疗法的最新进展和未来趋势。

综述目的：这篇综述对上消化道（GI）恶性肿瘤中人类表皮生长因子受体 2 (HER2)导向疗法的演变和现状进行了批判性评估，鉴于过去十年中治疗策略的动态变化，这是一项及时且具有相关性的研究。曲妥珠单抗治疗胃癌（ToGA）研究证明了曲妥珠单抗的疗效，但随后的试验显示进展有限，这使最初的热情遇到了障碍，突出了重新评估治疗方法和探索新型药物的必要性：综述强调了免疫检查点抑制剂和创新治疗技术的重大突破，它们重新定义了治疗范式，并在HER2阳性病例中显示出良好的疗效。曲妥珠单抗德鲁司坦（T-DXd）、扎尼达姆单抗和evorpacept等新兴疗法进一步说明了目前正在努力利用独特的作用机制来提高HER2阳性抗肿瘤活性。这些进展不仅反映了整合新型疗法组合的深远影响，还凸显了正在进行的研究在克服耐药机制和根据个体疾病特征进行治疗方面的关键作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Opinion in Oncology 医学-肿瘤学

CiteScore

6.10

自引率

2.90%

发文量

130

审稿时长

4-8 weeks

期刊介绍： With its easy-to-digest reviews on important advances in world literature, Current Opinion in Oncology offers expert evaluation on a wide range of topics from sixteen key disciplines including sarcomas, cancer biology, melanoma and endocrine tumors. Published bimonthly, each issue covers in detail the most pertinent advances in these fields from the previous year. This is supplemented by annotated references detailing the merits of the most important papers.